Format
Sort by
Items per page

Send to

Choose Destination

Links from Books

Items: 1 to 20 of 27

1.

TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments.

Vingerhoets J, Azijn H, Fransen E, De Baere I, Smeulders L, Jochmans D, Andries K, Pauwels R, de Béthune MP.

J Virol. 2005 Oct;79(20):12773-82.

2.

Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012.

Eshleman SH, Guay LA, Wang J, Mwatha A, Brown ER, Musoke P, Mmiro F, Jackson JB.

J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):24-9.

PMID:
16123677
3.

Long-term persistence of primary genotypic resistance after HIV-1 seroconversion.

Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, Green T, Kumar S, Murphy M, Tang A, Taylor S, White D, Underhill G, Pillay D, Cane P.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1570-3.

PMID:
15577410
4.

TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1.

Andries K, Azijn H, Thielemans T, Ludovici D, Kukla M, Heeres J, Janssen P, De Corte B, Vingerhoets J, Pauwels R, de Béthune MP.

Antimicrob Agents Chemother. 2004 Dec;48(12):4680-6.

5.

Clinical implications of stopping nevirapine-based antiretroviral therapy: relative pharmacokinetics and avoidance of drug resistance.

Mackie NE, Fidler S, Tamm N, Clarke JR, Back D, Weber JN, Taylor GP.

HIV Med. 2004 May;5(3):180-4.

6.
7.

An open-label assessment of TMC 125--a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance.

Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J, vant' Klooster GA.

AIDS. 2003 Dec 5;17(18):F49-54.

PMID:
14685068
8.

Genotype and phenotype at baseline and at failure in human immunodeficiency virus-infected antiretroviral-naive patients in a randomized trial comparing zidovudine and lamivudine plus nelfinavir or nevirapine.

Ferrer E, Podzamczer D, Arnedo M, Fumero E, McKenna P, Rinehart A, Pérez JL, Barberá MJ, Pumarola T, Gatell JM, Gudiol F; Combine Study Team.

J Infect Dis. 2003 Feb 15;187(4):687-90. Epub 2003 Jan 29.

PMID:
12599088
9.

Genotypic and phenotypic resistance patterns in early-stage HIV-1-infected patients failing initial therapy with stavudine, didanosine and nevirapine.

Vidal C, Arnedo M, Garcia F, Mestre G, Plana M, Cruceta A, Capon A, Gallart T, Miro JM, Pumarola T, Gatell JM.

Antivir Ther. 2002 Dec;7(4):283-7.

PMID:
12553483
10.

A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.

Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA.

AIDS. 2003 Jan 3;17(1):F1-5.

PMID:
12478089
11.

Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.

Whitcomb JM, Huang W, Limoli K, Paxinos E, Wrin T, Skowron G, Deeks SG, Bates M, Hellmann NS, Petropoulos CJ.

AIDS. 2002 Oct 18;16(15):F41-7.

PMID:
12370521
12.

The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis.

Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA; California Collaborative Treatment Group.

AIDS. 2002 Oct 18;16(15):F33-40.

PMID:
12370520
13.

Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure.

Antinori A, Zaccarelli M, Cingolani A, Forbici F, Rizzo MG, Trotta MP, Di Giambenedetto S, Narciso P, Ammassari A, Girardi E, De Luca A, Perno CF.

AIDS Res Hum Retroviruses. 2002 Aug 10;18(12):835-8.

PMID:
12201905
14.

Antiretroviral-drug resistance among patients recently infected with HIV.

Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, Koup RA, Mellors JW, Connick E, Conway B, Kilby M, Wang L, Whitcomb JM, Hellmann NS, Richman DD.

N Engl J Med. 2002 Aug 8;347(6):385-94.

15.

Extent and importance of cross-resistance to efavirenz after nevirapine failure.

Casado JL, Moreno A, Hertogs K, Dronda F, Moreno S.

AIDS Res Hum Retroviruses. 2002 Jul 20;18(11):771-5.

PMID:
12167268
16.

Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.

Cunningham CK, Chaix ML, Rekacewicz C, Britto P, Rouzioux C, Gelber RD, Dorenbaum A, Delfraissy JF, Bazin B, Mofenson L, Sullivan JL.

J Infect Dis. 2002 Jul 15;186(2):181-8. Epub 2002 Jun 26.

PMID:
12134253
17.

Genetic divergence of human immunodeficiency virus type 1 Ethiopian clade C reverse transcriptase (RT) and rapid development of resistance against nonnucleoside inhibitors of RT.

Loemba H, Brenner B, Parniak MA, Ma'ayan S, Spira B, Moisi D, Oliveira M, Detorio M, Wainberg MA.

Antimicrob Agents Chemother. 2002 Jul;46(7):2087-94.

18.

Acute HIV infection: impact on the spread of HIV and transmission of drug resistance.

Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, Telenti A, Battegay M, Veuthey AL, Bru JP, Rickenbach M, Hirschel B, Perrin L; Swiss HIV Cohort Study.

AIDS. 2001 Nov 23;15(17):2287-92.

PMID:
11698702
19.

Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Eshleman SH, Mracna M, Guay LA, Deseyve M, Cunningham S, Mirochnick M, Musoke P, Fleming T, Glenn Fowler M, Mofenson LM, Mmiro F, Jackson JB.

AIDS. 2001 Oct 19;15(15):1951-7.

PMID:
11600822
20.

Development of drug resistance in patients receiving combinations of zidovudine, didanosine and nevirapine.

Conway B, Wainberg MA, Hall D, Harris M, Reiss P, Cooper D, Vella S, Curry R, Robinson P, Lange JM, Montaner JS.

AIDS. 2001 Jul 6;15(10):1269-74.

PMID:
11426071

Supplemental Content

Support Center